- CEO Dr. Erik D Wiklund will provide a corporate update following the recently completed financing transactions
- CTO Dr. Thomas B Hansen will present new in vivo results demonstrating further validation and strengthening of circVec for gene therapy applications
Oslo, Norway, 19 February 2026 – Circio Holding ASA (OSE: CRNA), a biotechnology company developing novel circular RNA expression technology for gene and cell therapy, invites to a live webcast at 10:00am CET on Thursday 26 February 2026. Circio management will provide a corporate update and present recent in vivo results for the circVec circular RNA expression platform technology.
The webcast will feature an overview of circVec AAV development and include new data showcasing strong performance of circVec in new gene therapy areas, as well as further validation and characterization of previously presented results.
The corporate section will cover a summary of Circio´s recently completed, highly successful financing transactions and a business outlook for 2026.
Presenters:
CEO Dr. Erik Digman Wiklund
CTO Dr. Thomas Birkballe Hansen
Time: 10:00 CET on Thursday 26 February 2026
Click here to access Teams webcast
Meeting ID: 313 333 876 150 34
Passcode: 8SA24KF2
Questions can be submitted in advance by email to Erik D Wiklund: erik.wiklund@circio.com or directly in the live webcast
A recording of the webcast will be made available on the Circio webpage